Cold Plasma Market Research, 2033
The global cold plasma market size was valued at $2.3 billion in 2023 and is projected to reach $6.5 billion by 2033, growing at a CAGR of 11.1% from 2024 to 2033.
Market Introduction
Cold plasma, also known as non-thermal plasma, is a partially ionized gas with unique properties that distinguish it from hot plasmas typically found in stars or fusion reactors. Unlike thermal plasmas, cold plasma operates at near room temperature, making it safe for various end uses such as automotive, electronics, medical devices, and others. Its low temperature is achieved by generating a high voltage that ionizes the gas without significantly heating it. Cold plasma is characterized by its rich content of reactive species, including electrons, ions, and radicals, which enable it to interact with surfaces and biological tissues in beneficial ways. This technology has garnered significant interest for its potential in diverse fields such as medicine, where it is used for wound healing and sterilization, and environmental applications like air and water purification. Cold plasma's versatility and safety make it a promising tool for advancing numerous scientific and industrial processes.
Key Takeaways
- The cold plasma treatment market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($billion) for the projected period from 2024 to 2033.
- More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major cold plasma industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
- The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and to assist stakeholders in making informed decisions in order to achieve their most ambitious growth objectives.
Key Market Dynamics
The cold plasma industry is gaining adoption due to its numerous advantages, including low water and energy consumption, minimal fiber damage, reduced flammability, and low chemical utilization. It enhances wettability, is cost-effective, and worker friendly. In addition, rising awareness regarding cold plasma's effectiveness in treating infectious burns and aiding skin transplant wound healing is driving its demand. These benefits position cold plasma as a preferred choice in various applications, ensuring environmental sustainability and improved health outcomes, thus supporting cold plasma market growth.
Collaboration across scientific disciplines is essential for advancing cold plasma technology, yet coordination challenges hinder its widespread adoption. The intricate nature of cold plasma applications demands expertise from diverse fields like physics, chemistry, and engineering. However, integrating these disciplines into unified efforts remains a significant obstacle. This fragmented approach not only delays innovation but also limits the growth of demand for cold plasma solutions.
Cold plasma technology features low energy consumption and minimal chemical usage, significantly reducing its environmental footprint and aligning seamlessly with sustainability objectives. This eco-friendly approach accelerates the demand for cold plasma solutions, as industries seek efficient and environmentally responsible alternatives. By minimizing resource consumption and chemical emissions, cold plasma emerges as a major technology in advancing sustainability goals across various sectors. Its ability to deliver effective results while mitigating environmental impact boosts its growth trajectory and thus provide progressive cold plasma market opportunity.
Cold Plasma Market Analysis in the Healthcare Sector
Cold atmospheric plasma (CAP) has emerged as a majorly adopted source in the medical field, particularly for its ability to reduce wound bacterial contamination and enhance wound healing. Its application shows great potential in treating bedsores or pressure sores, which are common and challenging issues in healthcare. In addition, the effectiveness of CAP in preventing nosocomial infections significantly benefits the NHS by reducing the burden of these infections.
CAP's versatility extends across various medical applications, demonstrating efficacy without causing significant adverse effects on healthy cells. This makes it a valuable option for wound management. However, while CAP holds promise, it is crucial to acknowledge that its use can lead to potentially serious side effects. Therefore, it must be administered under expert supervision and in carefully controlled doses to ensure safety and effectiveness. By adhering to these precautions, CAP offers an innovative approach to wound care, minimizing infection risks and improving patient outcomes in a safe and controlled manner. In addition, rising medical spending by numerous countries across the globe is also expected to boost the cold plasma growth in the upcoming years.
Healthcare Expenditure as a Share of GDP of Major Economies, 2022
Countries | Healthcare Expenditure as a Share of GDP, 2022 |
U.S. | 0.81% |
Germany | 0.66% |
Switzerland | 0.51% |
France | 0.46% |
Sweden | 0.36% |
Source : AMR Analysis, Secondary Research
Market Segmentation
The cold plasma market share is segmented into regime, application, end user, and region. On the basis of regime, the market is divided into atmospheric pressure, and low pressure. As per application, the market is classified into surface treatment, sterilization & disinfection, coating & finishing, adhesion, wound healing, and others. Based on end user, the market is divided into automotive, electronics & semiconductors, food processing & packaging, healthcare, aerospace, and others. Region wise, the cold plasma market share is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Regional Market Outlook
North America is expected to dominate the global cold plasma market, holding the major share due to several factors. With a strong healthcare infrastructure and significant investments in R&D, the region is progressively adopting innovative technologies like cold plasma for various applications. In addition, the presence of key market players and collaborations between academic institutions and industry further boosts the market growth in this region. Cold plasma finds extensive utilization across diverse sectors including healthcare, food packaging, electronics, agriculture, and others. The stringent regulatory framework ensures the safety and efficacy of cold plasma technology, promoting its widespread adoption in North America. As consumer awareness regarding the benefits of cold plasma continues to increase, the region is expected to maintain its dominance in the global market, driving continuous advancements and thus supporting cold plasma market forecast.
- In February 2022, Perricone MD introduced the cold plasma plus+ concentrated treatment sheet mask, expanding its renowned collection. This innovative mask molds to facial contours, offering instant rejuvenation. Clinically proven, it reduces fine lines, sagging, uneven tone, enlarged pores, and dullness within six days. Utilizing a liquid crystal delivery system, it ensures rapid and deep ingredient absorption.
Competitive Landscape
The major players operating in the cold plasma market size include AcXys Plasma Technologies, Apyx Medical, Adtec Plasma Technology Co., Ltd., Enercon Industries Corporation, Coating Plasma Innovation, Henniker Plasma, Europlasma N.V., Nordson Corporation, Neoplas GmbH, and Plasmatreat GmbH.
Other players in the cold plasma market include P2i Limited, and Surfx Technologies, LLC.
Recent Key Strategies and Developments
- In March 2024, scientists in Canada utilized cold plasma techniques to target fungal mycotoxins, effectively reducing contamination in wheat and barley grains. This method enhances food safety and mitigates agricultural product losses. By reducing the levels of the major mycotoxins zearalenone and deoxynivalenol by 54% within one minute to one hour, this approach would increase the efficiency of the food & beverage industry. In addition, it boosts seed germination, which is expected to enhance beer production, providing significant benefits for both agriculture and brewing sectors.
Industry Trends
- In April 2024, Mirari Doctor launched the MIRARI cold plasma system, an advanced handheld device for skin rejuvenation and wound healing treatments. This innovative tool brings the power of cold plasma technology to healthcare professionals, offering precise, effective, and portable treatments. Cold plasma has shown significant potential in dermatology, wound care, and alternative cancer therapies. Mirari Doctor’s device revolutionizes patient care with its efficacy, cost-effectiveness, and safety, enhancing the overall patient experience. This launch positions Mirari Doctor at the forefront of medical technology, delivering advanced solutions for improved healthcare outcomes.
- To ensure that the ‘young’ cold plasma therapy will soon be reimbursed by health insurers, neoplas med GmbH submitted an application for testing in April 2021, which the Federal Joint Committee (G-BA) approved in February 2023. Now, neoplas med GmbH, terraplasma-medical GmbH, and Cinogy System GmbH have formed a consortium to commission the trial study as part of the method evaluation procedure by the G-BA. This collaboration aims to establish the efficacy and cost-effectiveness of cold plasma therapy, establishing the way for its acceptance and reimbursement by health insurers.
Key Sources Referred
- International Society for Plasma Medicine (ISPM)
- European Physical Society (EPS) - Plasma Physics Division
- Perricone MD
- Neoplas med GmbH
- Mirari Doctor
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cold plasma market analysis from 2023 to 2033 to identify the prevailing cold plasma market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the cold plasma market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
Apart from the points mentioned above, the report includes the analysis of the regional as well as global cold plasma market trends, key players, market segments, application areas, and market growth strategies.
Cold Plasma Market Report Highlights
| Aspects | Details |
 Market Size By 2033 | USD 6.5 Billion |
 Growth Rate | CAGR of 11.1% |
 Forecast period | 2024 - 2033 |
 Report Pages | 300 |
 By Regime |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Henniker Plasma, AcXys Plasma Technologies, Coating Plasma Innovation, Plasmatreat GmbH, Enercon Industries Corporation, Apyx Medical, Europlasma N.V., Neoplas GmbH, Nordson Corporation, Adtec Plasma Technology Co., Ltd. |
Cold plasma technology features low energy consumption and minimal chemical usage, significantly reducing its environmental footprint and aligning seamlessly with sustainability objectives.
The wound healing sub-segment is expected to dominate during the forecast period.
North America dominates the cold plasma market, primarily due to the significant presence of key industry players and the availability of numerous FDA-approved products.
The global cold plasma market was valued at $2.39 billion in 2023.
The major players operating in the cold plasma market include AcXys Plasma Technologies, Apyx Medical, Adtec Plasma Technology Co., Ltd., Enercon Industries Corporation, Coating Plasma Innovation, Henniker Plasma, Europlasma N.V., Nordson Corporation, Neoplas GmbH, and Plasmatreat GmbH.
Loading Table Of Content...
